Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $45.1 million.

  • Ultragenyx Pharmaceutical's Change in Accured Expenses rose 317.12% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year increase of 88.20%. This contributed to the annual value of $47.0 million for FY2024, which is 5115.54% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Change in Accured Expenses of $45.1 million as of Q3 2025, which was up 566.06% from -$9.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Change in Accured Expenses high stood at $57.4 million for Q2 2022, and its period low was -$48.5 million during Q1 2025.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Change in Accured Expenses value was $10.8 million (recorded in 2024), while the average stood at $3.2 million.
  • Examining YoY changes over the last 5 years, Ultragenyx Pharmaceutical's Change in Accured Expenses showed a top increase of 450.03% in 2021 and a maximum decrease of 338.45% in 2021.
  • Ultragenyx Pharmaceutical's Change in Accured Expenses (Quarterly) stood at $30.4 million in 2021, then decreased by 9.75% to $27.4 million in 2022, then crashed by 37.56% to $17.1 million in 2023, then surged by 170.85% to $46.4 million in 2024, then skyrocketed by 317.12% to $45.1 million in 2025.
  • Its last three reported values are $45.1 million in Q3 2025, -$9.7 million for Q2 2025, and -$48.5 million during Q1 2025.